Field evaluation of alternative HIV testing strategy with a rapid immunobinding assay and an agglutination assay
Identifieur interne : 001503 ( Main/Exploration ); précédent : 001502; suivant : 001504Field evaluation of alternative HIV testing strategy with a rapid immunobinding assay and an agglutination assay
Auteurs : S. W. Mitchell [États-Unis] ; D. S. Hanson [États-Unis] ; S. Mboup [Sénégal] ; J. Mingle [Ghana] ; D. Sambe [Zaïre] ; K. Milenge [Zaïre] ; P. Tukei [Royaume-Uni] ; J. Nyamongo [Kenya] ; O-K. Mubarak [Ghana] ; J-L. Sankale [Sénégal] ; T. C. Quinn [États-Unis]Source :
- The Lancet [ 0140-6736 ] ; 1991.
Descripteurs français
- KwdFr :
- Afrique, Anticorps anti-VIH (sang), Faux négatifs, Faux positifs, Humains, Immunotransfert, Sensibilité et spécificité, Séropositivité VIH (diagnostic), Technique de Western, Test ELISA, Tests d'agglutination, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie), VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (immunologie), Études d'évaluation comme sujet.
- MESH :
- diagnostic : Séropositivité VIH.
- immunologie : VIH-1 (Virus de l'Immunodéficience Humaine de type 1), VIH-2 (Virus de l'Immunodéficience Humaine de type 2).
- sang : Anticorps anti-VIH.
- Wicri :
English descriptors
- KwdEn :
- Academic freedom, Africa, Agglutination Tests, Agglutination test, Alternative strategy, Alternative testing strategy, Assay, Blot, Blotting, Western, Clin microbiol, Conventional procedure, Conventional strategy, Discrepant results, Disease control, Elisa, Elisa test, Enzyme-Linked Immunosorbent Assay, Evaluation Studies as Topic, False Negative Reactions, False Positive Reactions, Family health, Field conditions, Field laboratories, Genetic systems, Ghana, HIV Antibodies (blood), HIV Seropositivity (diagnosis), HIV-1 (immunology), HIV-2 (immunology), Hivchek, Human immunodeficiency virus, Human immunodeficiency virus type, Humans, Immunoblotting, Immunodeficiency, Immunosorbent assay, Initial results, Kenya, Mental disorder, Mental health, Mental illness, Mulanga kabeya, Predictive value, Rapid immunobinding assay, Rapid results, Rapid test, Rapid tests, Reactive, Reference laboratory, Screening test, Senegal, Sensitivity and Specificity, Standard elisa, Supplemental test, Technical assistance, Tenth specimen, Test results, Testing strategy, Western blot, Western blot testing, Western blots, Zaire.
- MESH :
- chemical , blood : HIV Antibodies.
- geographic : Africa.
- diagnosis : HIV Seropositivity.
- immunology : HIV-1, HIV-2.
- Teeft :
- Academic freedom, Agglutination Tests, Agglutination test, Alternative strategy, Alternative testing strategy, Assay, Blot, Blotting, Western, Clin microbiol, Conventional procedure, Conventional strategy, Discrepant results, Disease control, Elisa, Elisa test, Enzyme-Linked Immunosorbent Assay, Evaluation Studies as Topic, False Negative Reactions, False Positive Reactions, Family health, Field conditions, Field laboratories, Genetic systems, Ghana, Hivchek, Human immunodeficiency virus, Human immunodeficiency virus type, Humans, Immunoblotting, Immunodeficiency, Immunosorbent assay, Initial results, Kenya, Mental disorder, Mental health, Mental illness, Mulanga kabeya, Predictive value, Rapid immunobinding assay, Rapid results, Rapid test, Rapid tests, Reactive, Reference laboratory, Screening test, Senegal, Sensitivity and Specificity, Standard elisa, Supplemental test, Technical assistance, Tenth specimen, Test results, Testing strategy, Western blot, Western blot testing, Western blots, Zaire.
Abstract
A rapid immunobinding assay ('HIVCHEK', Ortho) and an agglutination assay ('Serodia-HIV', Fujirebio) were evaluated as an alternative to enzyme-linked immunosorbent assay (ELISA) and western blot under field conditions in Africa for detection of antibody to human immunodeficiency virus (HIV). 7106 specimens were tested at 25 laboratories in Kenya, Ghana, Senegal, and Zaire. HIVCHEK was used as a screening test, and serodia-HIV as a supplemental test to evaluate these assays in an alternative testing strategy to the standard ELISA/ western blot testing procedure. In each country, HIVCHEK was more sensitive and specific than ELISA when compared with western blot. The sensitivity of HIVCHEK ranged from 87·0 to 96·3% and the specificity from 99·0 to 100%. The sensitivity and specificity of serodia-HIV ranged from 85 to 98% and from 88 to 98%, respectively. The sensitivity and specificity were affected by the presence of HIV-2 in Ghana and Senegal. Overall, with an HIV-1 prevalence of 14·8% in Kenya and 22·5% in Zaire, the sensitivities of the alternative strategy were 96·4% and 91·4%, the specificities 99·6% and 100%, the positive predictive values 97·6% and 100%, and the negative predictive values 99·3% and 97·9% for Kenya and Zaire, respectively. With this testing format there was an estimated average cost saving of up to 82% over the conventional strategy with ELISA/western blot. This procedure constitutes a reasonable alternative to the standard ELISA/ western blot combination.
Url:
DOI: 10.1016/0140-6736(91)92991-A
Affiliations:
- Ghana, Kenya, Royaume-Uni, Sénégal, Zaïre, États-Unis
- Caroline du Nord, Maryland, Région du Grand Accra
- Accra
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000040
- to stream Istex, to step Curation: 000040
- to stream Istex, to step Checkpoint: 000918
- to stream Main, to step Merge: 001636
- to stream PubMed, to step Corpus: 000822
- to stream PubMed, to step Curation: 000822
- to stream PubMed, to step Checkpoint: 000822
- to stream Ncbi, to step Merge: 000206
- to stream Ncbi, to step Curation: 000206
- to stream Ncbi, to step Checkpoint: 000206
- to stream Main, to step Merge: 001623
- to stream Main, to step Curation: 001503
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Field evaluation of alternative HIV testing strategy with a rapid immunobinding assay and an agglutination assay</title><author><name sortKey="Mitchell, S W" sort="Mitchell, S W" uniqKey="Mitchell S" first="S. W." last="Mitchell">S. W. Mitchell</name></author><author><name sortKey="Hanson, D S" sort="Hanson, D S" uniqKey="Hanson D" first="D. S." last="Hanson">D. S. Hanson</name></author><author><name sortKey="Mboup, S" sort="Mboup, S" uniqKey="Mboup S" first="S." last="Mboup">S. Mboup</name></author><author><name sortKey="Mingle, J" sort="Mingle, J" uniqKey="Mingle J" first="J." last="Mingle">J. Mingle</name></author><author><name sortKey="Sambe, D" sort="Sambe, D" uniqKey="Sambe D" first="D." last="Sambe">D. Sambe</name></author><author><name sortKey="Milenge, K" sort="Milenge, K" uniqKey="Milenge K" first="K." last="Milenge">K. Milenge</name></author><author><name sortKey="Tukei, P" sort="Tukei, P" uniqKey="Tukei P" first="P." last="Tukei">P. Tukei</name></author><author><name sortKey="Nyamongo, J" sort="Nyamongo, J" uniqKey="Nyamongo J" first="J." last="Nyamongo">J. Nyamongo</name></author><author><name sortKey="Mubarak, O K" sort="Mubarak, O K" uniqKey="Mubarak O" first="O-K." last="Mubarak">O-K. Mubarak</name></author><author><name sortKey="Sankale, J L" sort="Sankale, J L" uniqKey="Sankale J" first="J-L." last="Sankale">J-L. Sankale</name></author><author><name sortKey="Quinn, T C" sort="Quinn, T C" uniqKey="Quinn T" first="T. C." last="Quinn">T. C. Quinn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9973950F5E17B827AD3460F6174334D179407408</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0140-6736(91)92991-A</idno><idno type="url">https://api.istex.fr/document/9973950F5E17B827AD3460F6174334D179407408/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000040</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000040</idno><idno type="wicri:Area/Istex/Curation">000040</idno><idno type="wicri:Area/Istex/Checkpoint">000918</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000918</idno><idno type="wicri:doubleKey">0140-6736:1991:Mitchell S:field:evaluation:of</idno><idno type="wicri:Area/Main/Merge">001636</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:1674306</idno><idno type="wicri:Area/PubMed/Corpus">000822</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000822</idno><idno type="wicri:Area/PubMed/Curation">000822</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000822</idno><idno type="wicri:Area/PubMed/Checkpoint">000822</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000822</idno><idno type="wicri:Area/Ncbi/Merge">000206</idno><idno type="wicri:Area/Ncbi/Curation">000206</idno><idno type="wicri:Area/Ncbi/Checkpoint">000206</idno><idno type="wicri:doubleKey">0140-6736:1991:Mitchell S:field:evaluation:of</idno><idno type="wicri:Area/Main/Merge">001623</idno><idno type="wicri:Area/Main/Curation">001503</idno><idno type="wicri:Area/Main/Exploration">001503</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Field evaluation of alternative HIV testing strategy with a rapid immunobinding assay and an agglutination assay</title><author><name sortKey="Mitchell, S W" sort="Mitchell, S W" uniqKey="Mitchell S" first="S. W." last="Mitchell">S. W. Mitchell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Family Health International, Research Triangle Park, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hanson, D S" sort="Hanson, D S" uniqKey="Hanson D" first="D. S." last="Hanson">D. S. Hanson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Family Health International, Research Triangle Park, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Mboup, S" sort="Mboup, S" uniqKey="Mboup S" first="S." last="Mboup">S. Mboup</name><affiliation wicri:level="1"><country xml:lang="fr">Sénégal</country><wicri:regionArea>University of Dakar, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Mingle, J" sort="Mingle, J" uniqKey="Mingle J" first="J." last="Mingle">J. Mingle</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>University of Ghana Medical School, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Sambe, D" sort="Sambe, D" uniqKey="Sambe D" first="D." last="Sambe">D. Sambe</name><affiliation wicri:level="1"><country xml:lang="fr">Zaïre</country><wicri:regionArea>Soins de Sante Primaires en Milieu Rurale, Kinshasa</wicri:regionArea><wicri:noRegion>Kinshasa</wicri:noRegion></affiliation></author><author><name sortKey="Milenge, K" sort="Milenge, K" uniqKey="Milenge K" first="K." last="Milenge">K. Milenge</name><affiliation wicri:level="1"><country xml:lang="fr">Zaïre</country><wicri:regionArea>Soins de Sante Primaires en Milieu Rurale, Kinshasa</wicri:regionArea><wicri:noRegion>Kinshasa</wicri:noRegion></affiliation></author><author><name sortKey="Tukei, P" sort="Tukei, P" uniqKey="Tukei P" first="P." last="Tukei">P. Tukei</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Virus Research Centre, Kenya Medical Research Institute </wicri:regionArea><wicri:noRegion>Kenya Medical Research Institute </wicri:noRegion></affiliation></author><author><name sortKey="Nyamongo, J" sort="Nyamongo, J" uniqKey="Nyamongo J" first="J." last="Nyamongo">J. Nyamongo</name><affiliation wicri:level="1"><country xml:lang="fr">Kenya</country><wicri:regionArea>National Public Health Laboratory Service Nairobi</wicri:regionArea></affiliation></author><author><name sortKey="Mubarak, O K" sort="Mubarak, O K" uniqKey="Mubarak O" first="O-K." last="Mubarak">O-K. Mubarak</name><affiliation wicri:level="3"><country xml:lang="fr">Ghana</country><wicri:regionArea>Noguchi Memorial Institute for Medical Research, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Sankale, J L" sort="Sankale, J L" uniqKey="Sankale J" first="J-L." last="Sankale">J-L. Sankale</name><affiliation wicri:level="1"><country xml:lang="fr">Sénégal</country><wicri:regionArea>Hôpital Le Dantec, Dakar</wicri:regionArea><wicri:noRegion>Dakar</wicri:noRegion></affiliation></author><author><name sortKey="Quinn, T C" sort="Quinn, T C" uniqKey="Quinn T" first="T. C." last="Quinn">T. C. Quinn</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The Lancet</title><title level="j" type="abbrev">LANCET</title><idno type="ISSN">0140-6736</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">337</biblScope><biblScope unit="issue">8753</biblScope><biblScope unit="page" from="1328">1328</biblScope><biblScope unit="page" to="1331">1331</biblScope></imprint><idno type="ISSN">0140-6736</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0140-6736</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Academic freedom</term><term>Africa</term><term>Agglutination Tests</term><term>Agglutination test</term><term>Alternative strategy</term><term>Alternative testing strategy</term><term>Assay</term><term>Blot</term><term>Blotting, Western</term><term>Clin microbiol</term><term>Conventional procedure</term><term>Conventional strategy</term><term>Discrepant results</term><term>Disease control</term><term>Elisa</term><term>Elisa test</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Evaluation Studies as Topic</term><term>False Negative Reactions</term><term>False Positive Reactions</term><term>Family health</term><term>Field conditions</term><term>Field laboratories</term><term>Genetic systems</term><term>Ghana</term><term>HIV Antibodies (blood)</term><term>HIV Seropositivity (diagnosis)</term><term>HIV-1 (immunology)</term><term>HIV-2 (immunology)</term><term>Hivchek</term><term>Human immunodeficiency virus</term><term>Human immunodeficiency virus type</term><term>Humans</term><term>Immunoblotting</term><term>Immunodeficiency</term><term>Immunosorbent assay</term><term>Initial results</term><term>Kenya</term><term>Mental disorder</term><term>Mental health</term><term>Mental illness</term><term>Mulanga kabeya</term><term>Predictive value</term><term>Rapid immunobinding assay</term><term>Rapid results</term><term>Rapid test</term><term>Rapid tests</term><term>Reactive</term><term>Reference laboratory</term><term>Screening test</term><term>Senegal</term><term>Sensitivity and Specificity</term><term>Standard elisa</term><term>Supplemental test</term><term>Technical assistance</term><term>Tenth specimen</term><term>Test results</term><term>Testing strategy</term><term>Western blot</term><term>Western blot testing</term><term>Western blots</term><term>Zaire</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique</term><term>Anticorps anti-VIH (sang)</term><term>Faux négatifs</term><term>Faux positifs</term><term>Humains</term><term>Immunotransfert</term><term>Sensibilité et spécificité</term><term>Séropositivité VIH (diagnostic)</term><term>Technique de Western</term><term>Test ELISA</term><term>Tests d'agglutination</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (immunologie)</term><term>Études d'évaluation comme sujet</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>HIV Antibodies</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Africa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>HIV Seropositivity</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Séropositivité VIH</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps anti-VIH</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Academic freedom</term><term>Agglutination Tests</term><term>Agglutination test</term><term>Alternative strategy</term><term>Alternative testing strategy</term><term>Assay</term><term>Blot</term><term>Blotting, Western</term><term>Clin microbiol</term><term>Conventional procedure</term><term>Conventional strategy</term><term>Discrepant results</term><term>Disease control</term><term>Elisa</term><term>Elisa test</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Evaluation Studies as Topic</term><term>False Negative Reactions</term><term>False Positive Reactions</term><term>Family health</term><term>Field conditions</term><term>Field laboratories</term><term>Genetic systems</term><term>Ghana</term><term>Hivchek</term><term>Human immunodeficiency virus</term><term>Human immunodeficiency virus type</term><term>Humans</term><term>Immunoblotting</term><term>Immunodeficiency</term><term>Immunosorbent assay</term><term>Initial results</term><term>Kenya</term><term>Mental disorder</term><term>Mental health</term><term>Mental illness</term><term>Mulanga kabeya</term><term>Predictive value</term><term>Rapid immunobinding assay</term><term>Rapid results</term><term>Rapid test</term><term>Rapid tests</term><term>Reactive</term><term>Reference laboratory</term><term>Screening test</term><term>Senegal</term><term>Sensitivity and Specificity</term><term>Standard elisa</term><term>Supplemental test</term><term>Technical assistance</term><term>Tenth specimen</term><term>Test results</term><term>Testing strategy</term><term>Western blot</term><term>Western blot testing</term><term>Western blots</term><term>Zaire</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Afrique</term><term>Faux négatifs</term><term>Faux positifs</term><term>Ghana</term><term>Humains</term><term>Immunotransfert</term><term>Kenya</term><term>Sensibilité et spécificité</term><term>Sénégal</term><term>Technique de Western</term><term>Test ELISA</term><term>Tests d'agglutination</term><term>Zaïre</term><term>Études d'évaluation comme sujet</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Liberté de l'enseignement</term><term>Santé mentale</term><term>Maladie mentale</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A rapid immunobinding assay ('HIVCHEK', Ortho) and an agglutination assay ('Serodia-HIV', Fujirebio) were evaluated as an alternative to enzyme-linked immunosorbent assay (ELISA) and western blot under field conditions in Africa for detection of antibody to human immunodeficiency virus (HIV). 7106 specimens were tested at 25 laboratories in Kenya, Ghana, Senegal, and Zaire. HIVCHEK was used as a screening test, and serodia-HIV as a supplemental test to evaluate these assays in an alternative testing strategy to the standard ELISA/ western blot testing procedure. In each country, HIVCHEK was more sensitive and specific than ELISA when compared with western blot. The sensitivity of HIVCHEK ranged from 87·0 to 96·3% and the specificity from 99·0 to 100%. The sensitivity and specificity of serodia-HIV ranged from 85 to 98% and from 88 to 98%, respectively. The sensitivity and specificity were affected by the presence of HIV-2 in Ghana and Senegal. Overall, with an HIV-1 prevalence of 14·8% in Kenya and 22·5% in Zaire, the sensitivities of the alternative strategy were 96·4% and 91·4%, the specificities 99·6% and 100%, the positive predictive values 97·6% and 100%, and the negative predictive values 99·3% and 97·9% for Kenya and Zaire, respectively. With this testing format there was an estimated average cost saving of up to 82% over the conventional strategy with ELISA/western blot. This procedure constitutes a reasonable alternative to the standard ELISA/ western blot combination.</div></front></TEI><affiliations><list><country><li>Ghana</li><li>Kenya</li><li>Royaume-Uni</li><li>Sénégal</li><li>Zaïre</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Maryland</li><li>Région du Grand Accra</li></region><settlement><li>Accra</li></settlement></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Mitchell, S W" sort="Mitchell, S W" uniqKey="Mitchell S" first="S. W." last="Mitchell">S. W. Mitchell</name></region><name sortKey="Hanson, D S" sort="Hanson, D S" uniqKey="Hanson D" first="D. S." last="Hanson">D. S. Hanson</name><name sortKey="Quinn, T C" sort="Quinn, T C" uniqKey="Quinn T" first="T. C." last="Quinn">T. C. Quinn</name></country><country name="Sénégal"><noRegion><name sortKey="Mboup, S" sort="Mboup, S" uniqKey="Mboup S" first="S." last="Mboup">S. Mboup</name></noRegion><name sortKey="Sankale, J L" sort="Sankale, J L" uniqKey="Sankale J" first="J-L." last="Sankale">J-L. Sankale</name></country><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Mingle, J" sort="Mingle, J" uniqKey="Mingle J" first="J." last="Mingle">J. Mingle</name></region><name sortKey="Mubarak, O K" sort="Mubarak, O K" uniqKey="Mubarak O" first="O-K." last="Mubarak">O-K. Mubarak</name></country><country name="Zaïre"><noRegion><name sortKey="Sambe, D" sort="Sambe, D" uniqKey="Sambe D" first="D." last="Sambe">D. Sambe</name></noRegion><name sortKey="Milenge, K" sort="Milenge, K" uniqKey="Milenge K" first="K." last="Milenge">K. Milenge</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Tukei, P" sort="Tukei, P" uniqKey="Tukei P" first="P." last="Tukei">P. Tukei</name></noRegion></country><country name="Kenya"><noRegion><name sortKey="Nyamongo, J" sort="Nyamongo, J" uniqKey="Nyamongo J" first="J." last="Nyamongo">J. Nyamongo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001503 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001503 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9973950F5E17B827AD3460F6174334D179407408
|texte= Field evaluation of alternative HIV testing strategy with a rapid immunobinding assay and an agglutination assay
}}
| This area was generated with Dilib version V0.6.31. |  |